First Republic Investment Management, Inc. Immunome Inc. Transaction History

First Republic Investment Management, Inc.

$34.7 Billion
Q3 2023

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 16, 2022	SELL	$2.24 - $5.79 $34,204 - $88,413	-15,270 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$3.88 - $13.99 $59,247 - $213,627	15,270 New	15,270 $87,000

Others Institutions Holding IMNM

# of Institutions

115

Shares Held

43.4M

Call Options Held

67.2K

Put Options Held

65.9K

Redmile Group, LLC San Francisco, CA

4.89M
Shares

$70.3 Million
3.86% of portfolio
Eco R1 Capital, LLC San Francisco, CA

3.88M
Shares

$55.8 Million
1.66% of portfolio
T. Rowe Price Investment Management, Inc. Baltimore, MD

3.88M
Shares

$55.8 Million
0.03% of portfolio
Black Rock Inc. New York, NY

3.76M
Shares

$54.1 Million
0.0% of portfolio
Janus Henderson Group PLC London, X0

3.16M
Shares

$45.5 Million
0.02% of portfolio

View Full List

About Immunome Inc.

Ticker IMNM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,127,400
Market Cap $174M
Description
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...

More about IMNM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of First Republic Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Republic Investment Management, Inc. with notifications on news.

Account